MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Ophthalmology, Optometry & Ocular Health (BioPharmaceuticals & Biotechnology)
Outlook Therapeutics, Inc. (NASDAQ: OTLK)*
Organization & Developments: Outlook Therapeutics
Parents
Outlook Therapeutics, Inc. (NASDAQ: OTLK)*
Children
*Clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO)
2019: Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer
2020: Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010
2020: Outlook Therapeutics: Not That Bright An Outlook
2021: The Outlook For Outlook Therapeutics
2023: Outlook Therapeutics: August PDUFA For Wet AMD Blockbuster_seekingalpha.com
2024: Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval_seekingalpha.com
2024: Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles
Jumps
Finance & Acquisitions: Outlook Therapeutics
Key People: Outlook Therapeutics